Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
CompanyDrug

Johnson & Johnson Officially Launches Spravato in China for Depression Treatment

Abbisko Therapeutics' ABSK131 Receives Clinical Trial Approval from China's NMPA
CompanyDrug

Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA

Cryofocus Biotechnology's Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market
CompanyMedical Device

Cryofocus Medtech’s Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market

Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)
CompanyDeals

Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)

Suzhou GenAssist's GEN6050X Receives FDA Clearance for Duchenne Muscular Dystrophy Treatment
CompanyDrug

Suzhou GenAssist’s GEN6050X Receives FDA Clearance for Duchenne Muscular Dystrophy Treatment

BioRay Biopharmaceutical's BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies
CompanyDrug

BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies

CStone Pharmaceuticals' CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma
CompanyDrug

CStone Pharmaceuticals’ CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma

Roche's Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment
CompanyDrug

Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment

Ascentage Pharma's Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment
CompanyDrug

Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment

ImmuneOnco's Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors
CompanyDrug

ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors

CSPC Pharma's JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors
CompanyDrug

CSPC Pharma’s JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors

Sandoz's Q4 2024 Results Show Strong Biosimilar Growth
Company

Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth